What are the most common Melanotan II side effects?

In the small human studies that exist, the most common were nausea and facial flushing — often severe enough to limit the dose — along with spontaneous penile erections and reduced appetite. Because Melanotan II activates all four melanocortin receptors non-selectively, its effects spread across pigmentation, appetite and arousal simultaneously. These are published research observations reproduced as a reference, not medical advice.

Does Melanotan II cause melanoma or mole changes?

The dermatology literature repeatedly reports darkening of existing moles and eruption of new atypical (dysplastic) nevi after use, including within 24 hours of a single injection in one case. There are also about four published melanoma case reports, all in people who injected the compound. Authors do not claim proven causation, and every reported patient had independent melanoma risk factors — but the change-in-moles signal is consistent and is exactly what dermatologists screen for.

Why is the dose so uncertain?

Because Melanotan II is sold unregulated. When Breindahl and colleagues analysed tanning products bought online in 2015, actual peptide content ranged from 4.32 to 8.84 mg against a 10 mg label. So the real exposure behind any effect is frequently unknown, which is one reason identity and content verification matters and why any adverse event is hard to attribute cleanly.

Why does this page point to PT-141 instead of Melanotan II?

Because Titan stocks PT-141 (bremelanotide), not Melanotan II. PT-141 is the MC4-weighted metabolite and is FDA-approved as Vyleesi, so it has a published label with a defined adverse-event table and pharmacokinetics — unlike Melanotan II, which has none. Titan supplies PT-141 strictly as a research-use-only reagent for in-vitro laboratory work, not for human or animal consumption. Nothing here is medical advice, and Titan does not sell Melanotan II.

Melanotan II · adverse-event profile · research use only

Melanotan II side effects, as the case-report literature actually documents them.

Melanotan II has no completed Phase III safety trial, so its adverse-event picture is assembled from small human studies and a scattered but consistent case-report record rather than a clean table. Two things stand out. The acute effects — nausea and facial flushing severe enough to be dose-limiting, spontaneous penile erections, reduced appetite — are well described. The concern that dominates the dermatology literature is different: repeated reports of pre-existing moles darkening and new atypical (dysplastic) nevi erupting, plus roughly four published melanoma case reports, all in people injecting the compound. This page reproduces that record as a research reference. One honesty note: Titan does not stock Melanotan II. It appears here as the parent structure for the MC4-selective, FDA-approved metabolite PT-141 (bremelanotide), which Titan does carry. It is a summary of published literature, not a human-use protocol or medical advice.

PT-141 nasal spray (MC4-selective) — $69.99 PT-141 vs Melanotan II

The acute effects are dose-limiting

In the small human studies that exist, nausea and facial flushing were common enough to limit the dose, alongside spontaneous penile erections and reduced appetite — the last being why it picked up the 'Barbie drug' nickname. Melanotan II is a non-selective agonist at all four melanocortin receptors (MC1, MC3, MC4, MC5), so its effects spread across pigmentation, appetite and sexual arousal at once rather than staying in one lane. These are the predictable, transient effects; the serious ones below are rarer but better documented.

Why the receptor spread matters →

The nevi concern is the recurring theme

This is what the dermatology literature keeps reporting. Schulze et al. (European Journal of Dermatology, 2014) described a 24-year-old who developed multiple new nevi and darkening of existing moles within 24 hours of a single subcutaneous injection. An Actas Dermo-Sifiliográficas case described more than 100 nevi — several severely dysplastic — after a 4-week course. Langan and Cousen reported similar transformations. The signal is consistent: existing moles darken and atypical nevi can erupt, which is exactly the change clinicians screen for.

How buyers evaluate the compound →

The melanoma case reports

A 2025 literature review counted four reported cases of melanoma potentially associated with Melanotan II, all involving subcutaneous administration — for example Paurobally described a 0.3 mm melanoma in an existing nevus about three months after injections. Authors are careful: a direct causal relationship is not established, and every reported patient carried independent risk factors (fair phototype, many moles, personal or family melanoma history, tanning-bed use). The honest reading is an unresolved signal in a high-risk group, not proof — which is precisely why the change-in-moles picture matters.

Research-use policy →

The rarer systemic reports

Beyond the skin, the case literature includes rhabdomyolysis with systemic toxicity (Nelson et al., Clinical Toxicology, 2012), ischemic priapism requiring intervention (Dreyer, BMJ Case Reports, 2019; Mallory, 2021), renal infarction (Peters et al., CEN Case Reports, 2020), posterior reversible encephalopathy syndrome (PRES), and exogenous hypercortisolism. These are individual reports, not incidence rates — but they are the reason regulators including the FDA, Ireland's HPRA and Australia's TGA have issued specific safety warnings about the compound.

PT-141 side effects →

The gray-market purity problem compounds everything

Because it is sold unregulated, what is in the vial is often not what the label claims. Breindahl et al. (Drug Testing and Analysis, 2015) analysed tanning products sold online and found actual peptide content of 4.32 to 8.84 mg against a 10 mg label — so the dose a user thinks they are taking is frequently wrong, and any adverse event is impossible to attribute cleanly. This is why identity and content verification is not a formality: an under- or over-filled vial changes the exposure behind every effect on this page.

How identity is verified →

Why this page points to PT-141

PT-141 (bremelanotide) is the MC4-weighted metabolite of Melanotan II and the compound Titan actually stocks. It is FDA-approved as Vyleesi for one narrow indication, which means — unlike Melanotan II — it has a published label with a defined adverse-event table and pharmacokinetics. Reading Melanotan II's messy, non-selective record makes the appeal of the more selective, better-characterised metabolite clear. This page does not imply Titan sells Melanotan II; it is referenced only as the structural parent.

PT-141 nasal spray — $69.99 →

The detail, in plain terms

The adverse-event record, at a glance.

Points below are drawn from small human studies, published case reports and regulatory notices, reproduced as a research reference. Melanotan II has no completed Phase III safety trial, so these are qualitative signals and individual cases — not incidence rates. Titan does not stock Melanotan II.

Nausea & flushing: Common in small human studies; often dose-limiting. Non-selective melanocortin activation.
Spontaneous erections: Well described — the MC4-mediated effect that led to the PT-141 program.
Appetite reduction: Reported; contributes to the 'weight-loss/tanning' misuse pattern.
Nevi darkening / eruption: Repeated case reports of existing moles darkening and eruptive dysplastic nevi (Schulze 2014; Langan; Cousen).
Melanoma: ~4 published case reports, all subcutaneous (e.g. Paurobally, 0.3 mm); causation not established; all patients high-risk.
Rhabdomyolysis: Case report with systemic toxicity (Nelson et al., Clin Toxicol 2012).
Priapism / renal infarction / PRES: Individual case reports (Dreyer 2019; Peters 2020); basis for FDA/HPRA/TGA warnings.
Vial content uncertainty: Gray-market vials measured 4.32–8.84 mg vs a 10 mg label (Breindahl 2015) — exposure often unknown.

Questions researchers ask

Before you order.

What are the most common Melanotan II side effects?: In the small human studies that exist, the most common were nausea and facial flushing — often severe enough to limit the dose — along with spontaneous penile erections and reduced appetite. Because Melanotan II activates all four melanocortin receptors non-selectively, its effects spread across pigmentation, appetite and arousal simultaneously. These are published research observations reproduced as a reference, not medical advice.
Does Melanotan II cause melanoma or mole changes?: The dermatology literature repeatedly reports darkening of existing moles and eruption of new atypical (dysplastic) nevi after use, including within 24 hours of a single injection in one case. There are also about four published melanoma case reports, all in people who injected the compound. Authors do not claim proven causation, and every reported patient had independent melanoma risk factors — but the change-in-moles signal is consistent and is exactly what dermatologists screen for.
What are the serious reported reactions?: The case-report record includes rhabdomyolysis with systemic toxicity, ischemic priapism requiring intervention, renal infarction, posterior reversible encephalopathy syndrome (PRES) and exogenous hypercortisolism. These are individual reports rather than incidence figures, but they are why the FDA, Ireland's HPRA and Australia's TGA have issued specific safety warnings about Melanotan II.
Why is the dose so uncertain?: Because Melanotan II is sold unregulated. When Breindahl and colleagues analysed tanning products bought online in 2015, actual peptide content ranged from 4.32 to 8.84 mg against a 10 mg label. So the real exposure behind any effect is frequently unknown, which is one reason identity and content verification matters and why any adverse event is hard to attribute cleanly.
Why does this page point to PT-141 instead of Melanotan II?: Because Titan stocks PT-141 (bremelanotide), not Melanotan II. PT-141 is the MC4-weighted metabolite and is FDA-approved as Vyleesi, so it has a published label with a defined adverse-event table and pharmacokinetics — unlike Melanotan II, which has none. Titan supplies PT-141 strictly as a research-use-only reagent for in-vitro laboratory work, not for human or animal consumption. Nothing here is medical advice, and Titan does not sell Melanotan II.